文拉法辛缓释剂对首发惊恐障碍的疗效及安全性观察

Venlafaxine Retarder's Efficacy and Safety in Treatment of Panic Disorder for First Time

目的观察文拉法辛缓释剂治疗首发惊恐障碍的治疗效果和安全性。方法对37例门诊首发惊恐障碍患者予以文拉法辛缓释剂治疗观察共6周,治疗前后采用汉密尔顿焦虑量表(HAMA,14项)评分观察疗效和国内统一4级疗效评定和比较,以及观察记录不良反应。结果①文拉法辛缓释剂治疗惊恐障碍的临床治愈率和总有效率分别为70.2%和91.9%。文拉法辛缓释剂治疗后的总分在第一周末就已经开始下降,并且差异有显著性(t=11.35,P<0.05);②37例患者治疗前后HAMA评分有明显改变,治疗过程中各时段两量表评分比较,差异均有显著性(P<0.05),并且文拉法辛缓释剂的疗效随治疗时间的延长而提高;③服药治疗6周后近90%患者的不良反应会自行缓解。结论文拉法辛缓释剂具有起效快,疗效好,安全性高,副作用轻微,依从性好的特点,不失为治疗首发惊恐障碍的首选药物。

bjective To explore the clinical effects of Venlafaxine retarder capsules in treating panic disorder. Methods 37 outpatients who occured for first time were treated with Venlafaxine for 6 weeks. And side effects were recorded as well. Results ①The clinical cure rate. and the total efficiency of Venlafaxine retarder were 70. 2% and 91.9%, The general scores stared to decline in the first weekend after treatment and there were significant differences （t= ll. 35, P〈0. 05）. ②Beforo and after treatment HAMA scores significantly changed. During the course of treatment, the differences of the scores of the two scales were significant （P〈0.05）, and the efficiency of Venlafaxine improved with the extension of time. ③The side reaction of near 90% patients eased after medication for 6 weeks. Conclusion Venlafaxine retorder have charateristics of rapid acting, good effect, light side reaction and better compliance, and it is a preferred drug in treatment of panic disorder.